207 related articles for article (PubMed ID: 26292025)
1. Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).
Li Z; Lu Y; Ahmad N; Strebhardt K; Liu X
Cell Cycle; 2015; 14(19):3030-9. PubMed ID: 26292025
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
3. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
4. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
[TBL] [Abstract][Full Text] [Related]
5. Insulin promotes proliferation of pancreatic ductal epithelial cells by increasing expression of PLK1 through PI3K/AKT and NF-κB pathway.
Wu K; Wang W; Chen H; Gao W; Yu C
Biochem Biophys Res Commun; 2019 Feb; 509(4):925-930. PubMed ID: 30642632
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
7. Plk1 phosphorylation of IRS2 prevents premature mitotic exit via AKT inactivation.
Chen L; Li Z; Ahmad N; Liu X
Biochemistry; 2015 Apr; 54(15):2473-80. PubMed ID: 25830382
[TBL] [Abstract][Full Text] [Related]
8. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
9. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.
Li Z; Li J; Bi P; Lu Y; Burcham G; Elzey BD; Ratliff T; Konieczny SF; Ahmad N; Kuang S; Liu X
Mol Cell Biol; 2014 Oct; 34(19):3642-61. PubMed ID: 25047839
[TBL] [Abstract][Full Text] [Related]
10. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
11. Modulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B.
Rafiee P; Binion DG; Wellner M; Behmaram B; Floer M; Mitton E; Nie L; Zhang Z; Otterson MF
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G865-77. PubMed ID: 20299603
[TBL] [Abstract][Full Text] [Related]
12. The scaffold protein TANK/I-TRAF inhibits NF-kappaB activation by recruiting polo-like kinase 1.
Zhang W; Wang J; Zhang Y; Yuan Y; Guan W; Jin C; Chen H; Wang X; Yang X; He F
Mol Biol Cell; 2010 Jul; 21(14):2500-13. PubMed ID: 20484576
[TBL] [Abstract][Full Text] [Related]
13. Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous cell carcinoma via impairing PLK1-AKT axis-mediated glycolysis.
Gao W; Zhang Y; Luo H; Niu M; Zheng X; Hu W; Cui J; Xue X; Bo Y; Dai F; Lu Y; Yang D; Guo Y; Guo H; Li H; Zhang Y; Yang T; Li L; Zhang L; Hou R; Wen S; An C; Ma T; Jin L; Xu W; Wu Y
Cell Death Dis; 2020 Oct; 11(10):919. PubMed ID: 33106477
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
[TBL] [Abstract][Full Text] [Related]
16. Plk1 phosphorylation of Numb leads to impaired DNA damage response.
Shao C; Chien SJ; Farah E; Li Z; Ahmad N; Liu X
Oncogene; 2018 Feb; 37(6):810-820. PubMed ID: 29059161
[TBL] [Abstract][Full Text] [Related]
17. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
19. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
Toosi B; Zaker F; Alikarami F; Kazemi A; Teremmahi Ardestanii M
Biomed Pharmacother; 2018 Jun; 102():428-437. PubMed ID: 29574283
[TBL] [Abstract][Full Text] [Related]
20. Tripping on TRIB3 at the junction of health, metabolic dysfunction and cancer.
Mondal D; Mathur A; Chandra PK
Biochimie; 2016 May; 124():34-52. PubMed ID: 26855171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
